I
I V Danilycheva
Researcher at Charité
Publications - 26
Citations - 1287
I V Danilycheva is an academic researcher from Charité. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 4, co-authored 18 publications receiving 713 citations.
Papers
More filters
Journal ArticleDOI
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria.
Torsten Zuberbier,Werner Aberer,Riccardo Asero,A H Abdul Latiff,Diane Baker,Barbara Ballmer-Weber,Jonathan A. Bernstein,Carsten Bindslev-Jensen,Zenon Brzoza,R Buense Bedrikow,G.W. Canonica,Martin K. Church,Timothy J. Craig,I V Danilycheva,Corinna Dressler,Luis Felipe Ensina,Ana Giménez-Arnau,Kiran Godse,Margarida Gonçalo,Clive Grattan,Jacques Hébert,Michihiro Hide,Allen P. Kaplan,Alexander Kapp,C. Katelaris,Emek Kocatürk,Kanokvalai Kulthanan,D. Larenas-Linnemann,Tabi A. Leslie,Markus Magerl,P. Mathelier-Fusade,R. Y. Meshkova,Martin Metz,Alexander Nast,Eustachio Nettis,Hanneke Oude-Elberink,Stefanie Rosumeck,Sarbjit S. Saini,Mario Sánchez-Borges,Peter Schmid-Grendelmeier,Petra Staubach,Gordon Sussman,Elias Toubi,Gino A. Vena,Christian Vestergaard,Bettina Wedi,Ricardo Niklas Werner,Zuotao Zhao,Marcus Maurer +48 more
TL;DR: In this paper, an evidence-and consensus-based guideline was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group.
Journal ArticleDOI
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria.
Torsten Zuberbier,Amir Hamzah Abdul Latiff,Mohamed Abuzakouk,S. Aquilina,Riccardo Asero,Diane Baker,Barbara Ballmer-Weber,Barbara Ballmer-Weber,Christine Bangert,Moshe Ben-Shoshan,Jonathan A. Bernstein,Carsten Bindslev-Jensen,Knut Brockow,Zenon Brzoza,Herberto José Chong Neto,Martin K. Church,Martin K. Church,Paulo Ricardo Criado,I V Danilycheva,Corinna Dressler,Luis Felipe Ensina,Luz Fonacier,Matthew Gaskins,Krisztián Gáspár,Aslı Gelincik,A. Giménez-Arnau,Kiran Godse,Margarida Gonçalo,Clive Grattan,Martine Grosber,Eckard Hamelmann,Jacques Hébert,Michihiro Hide,Allen P. Kaplan,Alexander Kapp,Aharon Kessel,Emek Kocatürk,Kanokvalai Kulthanan,Désirée Larenas-Linnemann,Antti Lauerma,Tabi A. Leslie,Markus Magerl,Markus Magerl,Michael Makris,R. Y. Meshkova,Martin Metz,Martin Metz,Daniel Micallef,Charlotte G. Mortz,Alexander Nast,Hanneke Oude-Elberink,Ruby Pawankar,Paolo D. Pigatto,Hector Ratti Sisa,María Isabel Rojo Gutiérrez,Sarbjit S. Saini,Peter Schmid-Grendelmeier,Bulent Enis Sekerel,Frank Siebenhaar,Frank Siebenhaar,Hanna Siiskonen,Angèle Soria,Petra Staubach-Renz,Luca Stingeni,Gordon Sussman,Andrea Szegedi,Simon Francis Thomsen,Zahava Vadasz,Christian Vestergaard,Bettina Wedi,Zuotao Zhao,Marcus Maurer,Marcus Maurer +72 more
TL;DR: This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS) on 3 December 2020 as mentioned in this paper, with the participation of 64 delegates of 50 national and international societies and from 31 countries.
Journal ArticleDOI
Ligelizumab for Chronic Spontaneous Urticaria
Marcus Maurer,Ana M Gimenez-Arnau,Gordon L Sussman,Martin Metz,Diane Baker,Andrea Bauer,Jonathan A. Bernstein,Randolf Brehler,Chia-Yu Chu,Wen-Hung Chung,I V Danilycheva,Clive Grattan,Jacques Hébert,Constance H. Katelaris,Michael Makris,R. Y. Meshkova,Sinisa Savic,Rodney Sinclair,Karl Sitz,Petra Staubach,Bettina Wedi,Jurgen Loffler,Avantika Barve,Kenneth Kobayashi,Eva Hua,Thomas Severin,Reinhold Janocha +26 more
TL;DR: A higher percentage of patients had complete control of symptoms of chronic spontaneous urticaria with ligelIZumab therapy of 72 mg or 240 mg than with omalizumab or placebo.
Journal ArticleDOI
Autoimmune Chronic Spontaneous Urticaria Detection with IgG Anti-TPO and Total IgE
Pavel Kolkhir,Pavel Kolkhir,Pavel Kolkhir,Elena Kovalkova,Anton A. Chernov,I V Danilycheva,Karoline Krause,Karoline Krause,Merle Sauer,Merle Sauer,Andrey E. Shulzhenko,Daria Fomina,Marcus Maurer,Marcus Maurer +13 more
TL;DR: In this paper, the authors investigated how high aTPO and low IgE individually and combined are linked to features of aiCSU, including treatment responses, and found that a TPO↑IgE↓ is a useful diagnostic marker for CSU in everyday clinical practice.
Journal ArticleDOI
Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: A one-year extension study.
Marcus Maurer,Ana Giménez-Arnau,Jonathan A. Bernstein,Chia-Yu Chu,I V Danilycheva,Michihiro Hide,Michael Makris,Martin Metz,Sinisa Savic,Karl Sitz,Weily Soong,Petra Staubach,Gordon Sussman,Avantika Barve,Alis Burciu,Eva Hua,Reinhold Janocha,Thomas Severin +17 more
TL;DR: In this paper, the authors evaluated the long-term safety and re-treatment efficacy of ligelizumab 240mg in patients who completed the core study and extension study, and the longterm safety profile was consistent with the core and extension studies.